Holen Sie sich die Stockscreener-App
290.19
1.17%
3.36
Schlusskurs vom Vortag:
$286.83
Offen:
$287.91
24-Stunden-Volumen:
443.16K
Relative Volume:
0.48
Marktkapitalisierung:
$13.85B
Einnahmen:
$4.03B
Nettoeinkommen (Verlust:
$-182.84M
KGV:
-77.17
EPS:
-3.7603
Netto-Cashflow:
$391.29M
1W Leistung:
-0.90%
1M Leistung:
-0.54%
6M Leistung:
+66.88%
1J Leistung:
+65.48%
1-Tages-Spanne:
$285.75
$290.61
1-Wochen-Bereich:
$284.61
$298.98
52-Wochen-Spanne:
$146.19
$303.31
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Compare CRL vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
290.19 | 13.98B | 4.03B | -182.84M | 391.29M | -3.7603 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-05-29 | Hochstufung | CLSA | Hold → Outperform |
| 2026-04-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-11-17 | Hochstufung | Argus | Hold → Buy |
| 2025-11-06 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-09-09 | Hochstufung | Jefferies | Hold → Buy |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories Stock: Company Reaffirms 2026 Guidance and Sets 2030 Targets - AD HOC NEWS
Charles River Labs Q3 Results: Adj EPS Expected At $2.90$3.00 - scanx.trade
UBS Upgrades Charles River Laboratories International to Buy From Neutral, Adjusts Price Target to $357 From $175 - Moomoo
Halper Sadeh investigates Charles River Labs over fiduciary breaches - scanx.trade
Here's How Much $1000 Invested In Charles River 15 Years Ago Would Be Worth Today - Benzinga
Is Aveanna Healthcare (AVAH) Stock Outpacing Its Medical Peers This Year? - Zacks Investment Research
UBS resumes Charles River Labs stock coverage with buy rating By Investing.com - Investing.com Australia
UBS resumes Charles River Labs stock coverage with buy rating - Investing.com
UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook - GuruFocus
Charles River Laboratories stock pre-market as Cooke & Bieler cites demand stabilization - AD HOC NEWS
Return on invested capital % of Charles River Laboratories International, Inc. – HAN:RV6 - TradingView
Charles River stock: Company reaffirms 2026 guidance and sets 2030 targets - AD HOC NEWS
Demand Stabilization Fuels Charles River Laboratories International’s (CRL) Recovery - Yahoo Finance
Charles River Laboratories International, Inc. Cash Flow – HAN:RV6 - TradingView
Charles River Laboratories stock trades near a yearly high as targets rise - AD HOC NEWS
Charles River Laboratories stock at USD 294.59 on September 28, 2026 - AD HOC NEWS
Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors? - Simply Wall Street
Is Charles River Laboratories Stock Outperforming the S&P 500? - Barchart.com
Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight Rating - moomoo.com
Charles River (NYSE:CRL) In Focus As Investor Day Unveils Pathway To Purpose And Lifts Near-Term View - Kalkine Media
Charles River Targets 5%-7% Growth, $300M Savings in 2030 Plan - Yahoo Finance
Charles River Labs stock sets USD 11.45 EPS outlook after Investor Day - AD HOC NEWS
Charles River Laboratories: Positive Investor Day Is Fully Priced In (NYSE:CRL) - Seeking Alpha
Mizuho raises Charles River Labs stock price target to $295 on outlook - Investing.com
RBC Raises Price Target on Charles River Laboratories International to $322 From $282, Keeps Outperform Rating - Yahoo Finance
Evercore ISI Adjusts PT on Charles River Laboratories International to $330 From $320, Maintains Outperform Rating - marketscreener.com
TD Cowen raises Charles River Labs stock price target on growth outlook - Investing.com Canada
Charles River Laboratories (CRL) Stock Still Seems Reasonable Despite Rapid Cell Banking Launch - Yahoo Finance
Charles River Labs stock rises 5.2 percent ahead of the open - AD HOC NEWS
Why Charles River Laboratories (CRL) Stock Is Up Today - Yahoo Finance
A Look at Charles River Laboratories International Inc (CRL) Aft - GuruFocus
Charles River Laboratories (CRL) Reaffirms 2026 Guidance and Unv - GuruFocus
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $325 FROM $300 - Bitget
CRL: 2030 targets: 5%-7% sales CAGR, ~24% margins, $300M savings, and digital-driven growth - TradingView
CRL: 2030 targets: 5%-7% sales CAGR, 24% margins, and $300M in savings via AI-driven modernization - TradingView
Charles River Laboratories International Jumps 5.1% in Broad Rally - AlphaStreet
Charles River Laboratories International Inc Stock (CRL) Moved Up by 7.23% on Sep 24: Facts Behind the Movement - TradingKey
Charles River Laboratories rises after reaffirming 2026 outlook and unveiling 2030 targets - Quiver Quantitative
Charles River Laboratories International (CRL) As Faster Cell Banking Fuels A Modest Undervalued View - Simply Wall Street
Charles River stock rises on promising 2026 outlook (CRL:NYSE) - Seeking Alpha
Everpure, Fervo Energy, Charles River Laboratories And Other Big Stocks Moving Higher On Thursday - Benzinga
Charles River Laboratories International, Inc. (CRL) Analyst/Investor DaySlideshow (NYSE:CRL) 2026-09-24 - Seeking Alpha
Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day - BioSpace
Charles River Laboratories International, Inc. Investor Day 2026 Transcript - gurufocus.com
Over $300M in savings is expected from 2027 to 2030 as Charles River (CRL) sets a revenue growth target. - Stock Titan
Charles River Labs reiterates FY26 outlook, targets 5-7% growth by 2030 - scanx.trade
Charles River Laboratories stock falls 2.73 percent after Q2 results - AD HOC NEWS
Charles River Laboratories Reaffirms Fiscal 2026 Guidance; Issues 2030 Growth Projections - marketscreener.com
CRL: 2030 targets: 5–7% organic revenue CAGR, ~24% margin, and $300M+ in cost savings - TradingView
CRL: Modernization and digitalization drive growth, with 5–7% organic revenue CAGR targeted by 2030 - TradingView
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):